Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded Sort descending |
---|---|---|---|---|---|---|---|---|
1R44HD107822-01
Show Summary |
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management | Cross-Cutting Research | Small Business Programs | NICHD | HILLMED, INC. | DIAS, NICHOLAS | Katy, TX | 2021 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Chronic pelvic pain affects social and sexual quality of life in up to 20% of women in the United States. It is often managed with physical therapy approaches, but when these measures fail, injection therapies may be indicated. These include injection of botulinum neurotoxin, which leads to muscle relaxation in the pelvic floor and thus pain relief. However, botulinum neurotoxin has dose-dependent side effects and is expensive. Therefore, a precision injection technique to administer botulinum neurotoxin so that it remains effective while minimizing adverse effects and costs is needed. Hillmed Inc. has developed a technique to assess the pelvic floor and choose the optimal injection site, which has improved treatment outcome in initial analyses. They are now aiming to develop a commercializable, personalized precision injection medical device for botulinum toxin and software package that will enable clinicians to optimize botulinum neurotoxin injection. They will then assess the system’s efficacy in a clinical trial of women with chronic pelvic pain and healthy women. |
||||||||
1R43NS124421-01A1
Show Summary |
Development of Nav1.7 Monoclonal Antibodies for Treating Pain | Cross-Cutting Research | Small Business Programs | NINDS | INTEGRAL MOLECULAR | RUCKER, JOSEPH BENJAMIN | Philadelphia, PA | 2021 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Many current pain relief treatments rely on use of opioid drugs. This research is conducting preclinical development on a non-addictive, non-opioid therapeutic that uses antibodies to target the sodium channel Nav1.7. This channel is known to be one of the primary routes for generating pain signals – thus it is a target for reducing pain. The antibody approach offers potential for greater specificity than small molecule approaches, potentially resulting in fewer side effects. |
||||||||
1R43NS120617-01A1
Show Summary |
Chemokine-receptor profiling for painful diabetic neuropathy in biological samples from human clinical trials | Cross-Cutting Research | Small Business Programs | NINDS | PLUMERIA THERAPEUTICS, INC. | RICHARDSON, THOMAS P (contact); WANG, YIPING | Plainsboro, NJ | 2021 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Chronic pain is a major healthcare burden. However, the types and underlying mechanisms of pain vary greatly, as do patient responses to currently available pain medications. Inflammation in the nervous system (neuroinflammation) is involved in several types of pain, and targeting key molecules involved in neuroinflammation is therefore a promising treatment approach. The chemokine receptor system, a complex network of more than 20 different receptors and more than 80 molecules that bind to these receptors, has a central role in neuroinflammation. Researchers do not yet fully understand the functioning of this network and how specific receptors vary in different chronic pain conditions. Therefore, this project aims to further characterize the expression of one specific receptor, using samples collected from participants in clinical trials evaluating a compound that interferes with the receptor’s function. This information should allow researchers to classify pain patients and identify those most likely to benefit from a treatment with compounds targeting the receptor. |
||||||||
1R43NS120410-01A1
Show Summary |
Optimization of a Gene Therapy for Chronic Pain in Human DRGs | Cross-Cutting Research | Small Business Programs | NINDS | NAVEGA THERAPEUTICS, INC. | MORENO, ANA MARIA (contact); ALEMAN GUILLEN, FERNANDO | La Jolla, CA | 2021 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: NS-20-011 Summary: To avoid the reliance on opioids for treatment of pain, researchers are investigating alternative approaches to disrupt the transmission of pain signals by specialized neurons in the body, such as dorsal root ganglion neurons in the spinal cord. Molecules called voltage-gated sodium channels that are located in the membranes of dorsal root ganglion neurons are essential for transmission of the pain signals. People carrying a specific variant of these channels, NaV1.7, are insensitive to pain; therefore, strategies to block this particular channel might help in the development of non-addictive pain treatment approaches. Navega Therapeutics is developing an innovative gene therapy that specifically targets NaV1.7. Using studies in human cell lines, they will identify the best designs to then test this gene therapy approach in human dorsal root ganglion neurons. |
||||||||
2R44NS115460-02
Show Summary |
Drug Free Nerve Block Device for the Relief of Pain and Symptoms in Migraines and other Headaches | Cross-Cutting Research | Small Business Programs | NINDS | THERMAQUIL, INC. | POPIELARSKI, STEPHEN (contact); YUAN, HSIANGKUO | Philadelphia, PA | 2021 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Migraines and other headaches are often debilitating for patients, yet few treatment options providing sustained relief exist. All available therapies, including frequently prescribed opioids, have considerable side effects or limitations. Therefore, novel treatment approaches are needed to reduce or eliminate the need to use opiates and other systemic pharmaceuticals. Thermaquil Inc. has developed a new way of stopping migraine and other headache pain by noninvasively blocking pain signal transmission in the head, which in initial studies allowed patients to discontinue use of opioids and other addictive pain medications. Thermaquil will now be conducting a larger randomized controlled trial to demonstrate the safety and effectiveness of this novel approach. After a baseline period, patients will be randomly assigned to the active or control condition and receive a single treatment. The study will continue for 12 weeks with the active versus control arms, before all patients will be given active therapy for an additional 12 weeks. |
||||||||
1R44GM140795-01A1
Show Summary |
Non-Opioid Post-Operative Pain Management Using Bupivacaine-loaded Poly(ester urea) Mesh | Cross-Cutting Research | Small Business Programs | NIGMS | 21MEDTECH, LLC | ALFARO, ARTHUR | Durham, NC | 2021 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: There is an urgent need for non-opioid post-operative pain management solutions. This research is developing a naturally absorbable polymer film that can release controlled amounts of the non-opioid analgesic bupivacaine – aiming to manage pain for several days following surgery. Project objectives are to optimize the timing of drug release, develop manufacturing standards, determine effective dosage for preserving motor function, and determine safety and efficacy in mouse models of neuropathic pain. Continued development of this film delivery system may lead to a new, non-opioid therapeutic strategy that could be combined with local anesthesia for up to 4 days after surgery to reduce or potentially eliminate opioids use. |
||||||||
1R41NS118992-01
Show Summary |
Development of selective calpain-1 inhibitors for chronic pain | Cross-Cutting Research | Small Business Programs | NINDS | 1910 GENETICS, INC. | NWANKWO, JENNIFER | Cambridge, MA | 2021 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: NS-20-011 Summary: The need to develop non-opioid therapeutics for chronic pain is greater than ever. One option being explored is inhibiting the activity of calpains – enzymes that have been shown to cause pain in animal models of chronic pain. Using an artificial intelligence (AI)-driven drug discovery platform, researchers have uncovered and validated four calpain-1 inhibitors using biochemical assays. This study by 1910 Genetics Inc. hopes to synthesize multiple analogs of its most potent discovered calpain-1 inhibitor and determine its effectiveness against calpain-2 and certain enzymes that break down proteins. Findings that successfully significantly inhibit calpain-1 in at least one animal model of chronic pain could lead to the first oral, central nervous system penetrating selective calpain-1 inhibitor [non-opioid therapeutic] for chronic pain. |
||||||||
1R43NS120335-01
Show Summary |
Closed-Loop Micromagnetic Neuromodulation as a Non-Opioid Treatment for Neuropathic Pain | Cross-Cutting Research | Small Business Programs | NINDS | QUANTUM NANOSTIM | REILLY, THOMAS | Treasure Island, FL | 2021 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Spinal cord stimulation (SCS) has been shown to provide effective relief for most people with chronic pain and eliminated the need for opioid therapy in more than half of those treated. However, traditional SCS approaches have encountered problems when glial cells coat the stimulation electrodes that distance the device from targeted neurons. This project will develop a novel hybrid Closed Loop Omnidirectional Neuromodulation with Electromagnetic fields (CLONE) system that is combined with magnetic-based stimulation to overcome glial coating of SCS electrodes, better target neurons in dorsal spine tissue, which may lead to better treatment of chronic neuropathic neck and low back pain. |
||||||||
1R44NS119036-01
Show Summary |
Development of a novel analgesic for mixed inflammatory and neuropathic pain states | Cross-Cutting Research | Small Business Programs | NINDS | ANABIOS CORPORATION | GHETTI, ANDREA | San Diego, CA | 2021 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: As prescription opioid drug abuse and overdose-related deaths continue to skyrocket in the United States, the need for new and more effective non-addictive pain drugs to treat chronic pain remains critical. This research is conducting studies in animal models of a small molecule that has high potential to treat chronic pain conditions associated with neuropathy and/or inflammation. The goal of this project is to conduct dosing and other studies leading up to an animal model study of the potential drug in a toxicology study for 28 days. Results may lead to Investigative New Drug regulatory clearance to begin clinical studies to validate the potential drug’s efficacy and safety. |
||||||||
3UH3DA047925-03S1
Show Summary |
Development of a 3-Month Implantable Depot Pellet of Naltrexone for the Treatment of Opioid Use Disorder | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | BIOCORRX, INC. | MALLON, ANDREW PETER | Anaheim, CA | 2022 |
NOFO Title: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
NOFO Number: NOT-OD-22-033 Summary: This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. |
||||||||
3UM1NS118922-03S2
Show Summary |
Transition from Acute to Chronic Pain After Thoracic Surgery | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NINDS | UNIVERSITY OF MICHIGAN | BRUMMETT, CHAD M; CHANG, ANDREW CHING-HUNG; CLAUW, DANIEL J; WALJEE, JENNIFER FILIP | Ann Arbor, MI | 2022 |
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-22-066 Summary: Rigorous and impactful clinical pain research requires participant diversity that reflects the racial/ethnic diversity of affected populations. This project will enhance patient and other community engagement, particularly of underrepresented minorities, to participate in clinical research related to the transition of acute to chronic pain. |
||||||||
1R61DA057675-01
Show Summary |
Using System Dynamics Modeling to Foster Real-Time Connections to Care | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | YALE UNIVERSITY | HECKMANN, REBEKAH (contact); S SABOUNCHI, NASIM | New Haven, CT | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 Summary: First responders prevent many overdose deaths by providing life-saving resuscitation and giving naloxone to reverse an opioid overdose. This project will use a modeling approach to assess the impact of Good Samaritan Laws that protect people from certain criminal penalties if they call 911 to save an overdose victim by giving naloxone on overdose mortality. This research will develop and test a novel, scalable, telehealth platform that can be used at the time of an opioid overdose to link patients with access to medication for opioid use disorder, harm reduction services, and recovery support. The research will be informed by patient-outcome data. |
||||||||
3U2COD023375-07S1
Show Summary |
ACT-NOW Data Sustainability - ECHO Administrative Supplement | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | OD/ECHO | DUKE UNIVERSITY | SMITH, PHILLIP BRIAN; NEWBY, LAURA KRISTIN | Durham, NC | 2022 |
NOFO Title: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
NOFO Number: NOT-OD-22-110 Summary: This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. |
||||||||
3UH3AR077360-04S1
Show Summary |
A sequenced-strategy for improving outcomes in patients with knee osteoarthritis pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | JOHNS HOPKINS UNIVERSITY | CAMPBELL, CLAUDIA MICHELLE (contact); CASTILLO, RENAN C; COHEN, STEVEN P | Baltimore, MD | 2022 |
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: PA-21-071 Summary: Knee osteoarthritis is one of the leading causes of chronic pain and disability worldwide, affecting more than 30% of older adults. Rates of this condition have more than doubled in the past 70 years and continue to grow sharply, given increases in life expectancy and body mass index among the U.S. population. This project supports a scientist from a group underrepresented in biomedicine to expand ongoing clinical research comparing various non-medication-based treatments for knee osteoarthritis. |
||||||||
3R01DE029202-01S2
Show Summary |
Validation of Blocking TSP4/Cava2d1 Interaction as a New Target for Neuropathic Pain | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDCR | UNIVERSITY OF CALIFORNIA-IRVINE | LUO, ZHIGANG DAVID | Irvine, CA | 2022 |
NOFO Title: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
NOFO Number: NOT-OD-22-033 Summary: This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. |
||||||||
1R21AT012431-01
Show Summary |
Psychosocial Risk Factors for Chronic Pain: Characterizing Brain and Genetic Pathways and Variation Across Understudied Populations | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NCCIH | DARTMOUTH COLLEGE | WAGER, TOR D | Hanover, NH | 2022 |
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011 Summary: Fifty million Americans experience chronic pain, including about 25 million who report pain that substantially interferes with daily activities and reduces quality of life. Mental health problems, including depression, anxiety, and post-traumatic stress disorder, increase risk for severe chronic pain. This project will use genetic data, information about observable characteristics (phenotypic data), and neuroimaging data from three large databases to identify psychosocial factors that predict chronic pain, assess differences across diverse U.S. populations, and determine whether risk profiles predict post-surgical chronic pain. |
||||||||
1R61DA057667-01
Show Summary |
CADENCE – Continuous and Data-drivEN CarE | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | UNIVERSITY OF SOUTH FLORIDA | FRYER, KIMBERLY (contact); MARSHALL, JENNIFER | Tampa, FL | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 Summary: Maternal opioid use disorder is the leading cause of death for women who die within a year of giving birth. Many pregnant women do not have access to prenatal care and medications known to be standard of care for opioid use disorder. This project will create, measure, and evaluate costs for an interactive dashboard that collects and analyzes data about maternal, newborn, and infant outcomes for pregnancies affected by opioid use disorder. This research will also monitor mothers’ use of medications for opioid use disorder and the number of infants born with neonatal withdrawal syndrome that require medication treatment. |
||||||||
3R24DA055306-01S1
Show Summary |
Wake Forest IMPOWR Dissemination Education and Coordination Center (IDEA-CC) | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDA | WAKE FOREST UNIVERSITY HEALTH SCIENCES | ADAMS, MEREDITH C B | Winston-Salem, NC | 2022 |
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272 Summary: This research provides support to strengthen data management, data sharing, and data readiness efforts within the HEAL Initiative. This support further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. It also provides an opportunity for existing HEAL Initiative award recipients to increase data “FAIR”-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. |
||||||||
3UH3CA261067-03S1
Show Summary |
Optimizing the use of ketamine to reduce chronic postsurgical pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NCI | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | WANG, JING (contact); DOAN, LISA | New York, NY | 2022 |
NOFO Title: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
NOFO Number: RFA-NS-20-028 Summary: Approximately 20% of patients who undergo surgery develop chronic Postsurgical Pain, which is linked with slow recovery, persistent opioid use and dependence. This project supports a scientist from a group underrepresented in biomedicine to expand ongoing research testing ketamine during and/or after surgery to prevent post-mastectomy pain syndrome. Ketamine is a low-risk treatment option that is easy to implement in a wide range of clinical settings. |
||||||||
1DP2NS130454-01
Show Summary |
Using Mouse Pain Scales to Discover Unusual Pain Sensitivity and New Pain Targets | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NINDS | COLUMBIA UNIV NEW YORK MORNINGSIDE | ABDUS-SABOOR, ISHMAIL JOHN | New York, NY | 2022 |
NOFO Title: Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-22-013 Summary: Acute and chronic pain vary widely across patients, due in large part to genetic differences between individuals. The same variation occurs in preclinical animal models with diverse genetic backgrounds. The development of automated mouse “pain scales” using high-speed videography, machine learning, and custom software allows pain to be assessed in a quantitative manner in nonverbal animals. This technology will be used to identify genetically different mice with high or low pain sensitivity, which will facilitate the development of new therapeutic strategies to treat pain and reduce reliance on opioids. |
||||||||
1R21DE032532-01
Show Summary |
Secondary Analysis and Integration of Existing Data Related to Chronic Orofacial Pain and Placebo Effects | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIDCR | UNIVERSITY OF MARYLAND, BALTIMORE | COLLOCA, LUANA (contact); DORSEY, SUSAN G | Baltimore, MD | 2022 |
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011 Summary: Temporomandibular joint (TMJ) disorders, which affect the joint connecting the lower jaw and the skull, are common and difficult chronic pain conditions. Pain management strategies that harness the body’s own pain relief mechanisms (including placebo effects in which pain relief cannot be attributed to a specific treatment), can reduce the severity and duration of TMJ-related chronic pain. Although research suggests that placebo effects may have a genetic basis, few, if any, genetic studies have examined this possibility in individuals with TMJ disorders. This project will use in-depth genetic, sociodemographic, clinical, and psychological data collected from adults with chronic TMJ disorders to better understand how the placebo effect works. |
||||||||
1R61DA057600-01
Show Summary |
Using Data to Drive Action to Reduce Opioid Overdoses in Seattle, WA | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | UNIVERSITY OF WASHINGTON | BANTA-GREEN, CALEB (contact); HOOD, JULIA ELIZABETH | Seattle, WA | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 Summary: This project will use a data-to-action framework to guide implementation of opioid use disorder treatment and harm reduction interventions based on rapid data analysis. It will leverage existing data systems such as Emergency Medical Services (EMS) reports, mobile integrated health case management data, and medical examiner data for near real-time data analyses, visualization, and action planning. This research will collect a range of data (opioid treatment, use of acute care services, morbidity, mortality, incarceration, housing support, and cost benefits) from a sub-acute stabilization center for people at high risk for opioid overdose, including those who have recently overdosed and are referred and transported by EMS teams. |
||||||||
1R43CA268700-01A1
Show Summary |
Pre-clinical Validation of Phase II Peptide LRP-1 Agonist to Treat and Prevent Chemotherapy Induced Peripheral Neuropathy | Cross-Cutting Research | Small Business Programs | NCI | SERPIN PHARMA, LLC | GELBER, COHAVA (contact); CAMPANA, WENDY M | Manassas, VA | 2022 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will develop and test a new type of treatment (reduced size cyclic analogs) for this condition. The research will evaluate the ability of this therapy to reduce inflammation and pain, as well as to repair nerve damage. |
||||||||
3UM1DA049412-04S1
Show Summary |
MassHEAL - Reducing overdose deaths by 40% (2019-2023) | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | BOSTON MEDICAL CENTER | SAMET, JEFFREY | Boston, MA | 2022 |
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: PA-21-071 Summary: Although there are effective prevention and treatment programs and services to address opioid misuse, opioid use disorder, and overdose, gaps remain between those needing and those receiving prevention and treatment. There is a need to better understand how to make these programs and services most effective at a local level, a problem being addressed by the HEALing Communities Study. This project supports a scientist from a group underrepresented in biomedicine to continue ongoing work to test the impact of an integrated set of evidence-based practices across health care, behavioral health, justice, and other community-based settings. |
||||||||
3R01NS118563-01A1S1
Show Summary |
Diversity Supplement to FKBP51 Antagonism to Prevent Chronic Pain: Optimizing Efficacy & Evaluating Safety and Mechanisms | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NINDS | UNIV OF NORTH CAROLINA CHAPEL HILL | LINNSTAEDT, SARAH; MCLEAN, SAMUEL A | Chapel Hill, NC | 2022 |
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: NOT-NS-20-107; PA-21-071 Summary: Current evidence indicates that chronic pain after a traumatic injury is influenced by the body’s response to stress. This project will conduct a comprehensive analysis of gene expression after traumatic stress exposure in a range of animal models in various body regions including the brain (amygdala, hippocampus, hypothalamus) and spinal cord, as well as nerves and immune cells throughout the body. These studies will be conducted in animals with no stress exposure as well as in animals treated with a molecule (FKBP51) known to block the stress response. This research will enhance understanding of how FKBP51 and post-injury stress affect pain processes. |